We report the first case of prosthetic joint infection caused by Mycobacterium alvei, which was identified by PCR-restriction fragment length polymorphism and verified by analysis of nucleotide sequences of its amplified 16S ribosomal DNA. The pathogen was susceptible to linezolid, amikacin, ciprofloxacin, tigecycline, and trimethoprim-sulfamethoxazole. The clinical implications are discussed.
CASE REPORT
A 75-year-old woman received hemiarthroplasty and underwent bipolar endoprosthesis replacement for osteoarthritis involving her left knee. She had received numerous intra-articular injections of steroids for pain relief over her left knee before this procedure. Pain, redness, and swelling began insidiously developing over her left knee 2 months after the arthroplastic surgery. Laboratory tests disclosed an elevated erythrocyte sedimentation rate (ESR, 125 mm/h [normal is Ͻ20 mm/ h]). Her chest radiograph was normal. During left-knee arthroscopic surgery, prosthetic implant loosening with extensive periprosthetic tissue necrosis was found. Analysis of synovial fluid revealed a leukocyte count of 10,424 cells/l with 75% polymorphonuclear cells. Synovial fluid was negative for Gram staining and for aerobic and anaerobic bacterial cultures. The histopathology of the excised synovial tissue suggested acute and chronic inflammation. Resection arthroplasty was performed, and antibiotic-loaded cement beads (vancomycin, piperacillin, and amikacin in polymethylmethacrylate [PMMA]) were implanted. The patient then received intravenous teicoplanin injection for 4 weeks, followed by oral fusidic acid and rifampin for maintenance therapy, because methicillin-resistant Staphylococcus aureus was assumed to be the most likely culprit pathogen for her prosthetic joint infection (PJI).
Three months later, her PJI did not improve clinically, and her ESR was 151 mm/h, suggesting an intractable infection. A computed tomography scan revealed an edematous change in the muscular structure around the left knee and a loculated abscess located medial to the tibialis posterior. A pocket with yellowish necrotic tissue-like content in the soft tissue near the synovial membrane of the left knee was found at an exploratory surgery. The histopathology of the excised synovial membrane disclosed granulomatous inflammation with the presence of multinucleated giant cells. Both acid-fast staining and Gram staining were negative. Culture of the excised synovium by spreading it on 5% sheep blood agar for 48 h of incubation turned out to be negative. Spreading of the excised synovium on egg-based Lowenstein-Jensen slants (bioMérieux, La Balme-les-Grottes, France) incubated at 37°C with 10% CO 2 developed scanty, buff-colored, rough colonies 2 weeks later. Microscopic examinations revealed short Gram-positive bacilli and acid-fast bacilli that formed clumps. Conventional biochemical reactions revealed a negative niacin test result and a positive nitrate reductase test result, suggesting that the acidfast bacilli were nontuberculous mycobacteria. Identification of the isolated acid-fast bacilli started with PCR-restriction fragment length polymorphism (RFLP) using oligonucleotide primers MOTT-11 and MOTT-12 (5Ј-ACCAACGATGGTGT GTCCCAT-3Ј and 5Ј-CTTGTCGAACCGCATACCCT-3Ј) for amplification of the 439-bp fragment of the hsp65 gene (12), followed by sequential digestions of PCR products each using restriction enzymes BstEII, HhaI, and HaeIII. The digested PCR products were then separately analyzed by agarose gel electrophoresis, which showed RFLP patterns similar to those of Mycobacterium alvei (3) . To verify the identification, the partial 16S rRNA gene was amplified by PCR using universal forward primer 27F (5Ј-AGAGTTTGATCCTGGCTC AG-3Ј) and universal reverse primer 907R (5Ј-CCGTCAATT CCTTTGAGTTT-3Ј) (16) . Two PCR products, each with nucleotides 881 and 860, were sequenced with a 310 Genetic Analyzer (ABI Prism) and were compared to those searched from the GenBank database (http://blast.ncbi.nlm.nih.gov /BLAST.cgi). The two DNA samples were found to be a 100% match with the sequence of M. alvei. The growth of our isolate was in agreement with a previous publication reporting that, when cultured with Lowenstein-Jensen medium, M. alvei grew between 10 and 15 days at 37°C; M. alvei may grow within 5 days at 30°C (1). Antimicrobial susceptibilities were determined using the broth microdilution method, and the antibiotics included in the tests were as follows: amikacin, cefoxitin, imipenem, ciprofloxacin, trimethoprim-sulfamethoxazole (all purchased from Sigma, St. Louis, MO), clarithromycin (Abbott, Abbott Park, IL), linezolid, and tigecycline (Pfizer, New York, NY). Interpretations of susceptibility to the tested antibiotics, except for tigecycline and linezolid, were according to NCCLS/ Clinical and Laboratory Standards Institute (CLSI) criteria (11) . The breakpoints of linezolid and tigecycline for rapidly growing mycobacteria (RGM) have not yet been addressed by the CLSI. However, these two antimicrobial agents were recognized as active against some RGM isolates (6). The breakpoints used for linezolid and tigecycline susceptibility were those proposed by Wallace et al. (14, 15) . The susceptibility testing disclosed that the M. alvei isolate was susceptible to amikacin, ciprofloxacin, trimethoprim-sulfamethoxazole, linezolid, and tigecycline but not to cefoxitin, imipenem, and clarithromycin ( Table 1) .
The patient received intravenous therapy with tigecycline and amikacin for 4 weeks, followed by oral ciprofloxacin and trimethoprim-sulfamethoxazole for the subsequent 6 months. Her ESR value was 24 mm/h on completion of the antibiotic therapy. Endoprosthesis replacement for her left knee was performed, and it remained uneventful when the patient was last seen 6 months later.
M. alvei, an RGM, was first isolated from water, soil, and human sputum in 1992 (1). Being ubiquitously distributed in environmental sources, M. alvei may occasionally be found in respiratory secretions of humans as a colonizer. To our knowledge, only one patient with a lung infection (1) and a cat with pyogranulomatous panniculitis (2) caused by M. alvei have been reported thus far. RGM isolates that have been reported to be etiological agents for PJI include M. fortuitum, M. chelonae, M. abscessus, and M. smegmatis but not M. alvei (4, 8) . Joint infections caused by RGM are usually acquired by inoculation of the pathogen from the contaminated sources by injury, needle injection, or surgery (4).
Because of clinical similarities between arthritis caused by RGM and by other commonly encountered pathogens, such as Staphylococcus spp. and Pseudomonas aeruginosa (13) , and because of the lack of widespread clinician awareness of arthritis due to RGM, resulting from its rarity, the chances that clinicians will fail to make a timely diagnosis of RGM-associated PJI are high. It is probably the fact that the patient's specimens were not intentionally processed for the recovery of acid-fast bacilli that led to the M. alvei being missed initially in this reported case. To avoid missing any rarely encountered pathogen, clinicians should sample the aspirated synovial fluid and/ or exudative material from the explored septic arthritis and send it to a microbiology laboratory for culture for aerobic and anaerobic bacteria in general and for acid-fast bacilli in particular.
Despite being able to grow on a blood agar, it usually takes 5 days for an RGM to develop visible colonies (5) , and the culture agar plates are often discarded before that based on the standard procedures adopted by most clinical laboratories. Characteristically, the histopathology of the RGM-affected synovial tissue sampled at exploratory surgery reveals granulomatous inflammation with or without the presence of multinucleated giant cells (10) , which is unfortunately not Mycobacterium species specific. Under these circumstances, clinicians usually empirically start antituberculosis therapy, as tuberculosis is more prevalent than infections caused by other Mycobacterium spp. in some settings. The commonly used antituberculosis drugs, such as isoniazid, ethambutol, and rifampin, are unfortunately more often than not inactive against RGM. A high index of suspicion for RGM infections is therefore extremely important. Previous reports (9, 10) and ours suggest that patients with a history of localized trauma or intra-articular injection of steroids, regardless of their immunity status, are at high risk for septic arthritis due to RGM.
Once an RGM is isolated, laboratory staff may differentiate M. alvei from M. fortuitum and M. chelonae by the microbe's failure to grow on MacConkey agar without crystal violet, as well as failure to degrade salicylate, and by its inability to grow in the presence of picric acid, ethambutol, kanamycin, capreomycin, and isoniazid (1) . The identification of a mycobacterium to its species level and the availability of its antibiotic susceptibility profile are equally important, because antimicrobial therapy for PJI due to RGM should be guided by the microbe's susceptibility profile as a result of the possible interand intraspecies variability in antimicrobial susceptibility among mycobacteria (6, 7) . Reported information about in vitro antimicrobial activities against M. alvei has been very limited thus far (6) , and there is insufficient clinical and laboratory information in the published literature to make recommendations on how to treat infections caused by such a pathogen. However, the favorable MICs against RGM isolates (6, 14, 15) in previous reports and ours suggest that tigecycline and linezolid are potentially therapeutically useful for infections due to M. alvei. Further accumulation of reports on experiences with M. alvei infections is needed to help map out a recommended therapeutic strategy. 
